Cethromycin HCl is being developed as a short-course, G6PD-independent therapy designed to eliminate liver-stage malaria parasites and prevent relapse.

• IND-enabling studies funded and planned for Q1/Q2 2026
• cGMP API manufacturing completed Q1 2026
• Phase I and Phase II a Controlled Human Malaria Infection (CHMI) studies planned
• Regulatory strategy aligned with expedited pathways

Based on its intended indication and development pathway, Cethromycin HCl may be eligible for established U.S. regulatory programs including Fast Track and Breakthrough Therapy designation, Priority Review , Tropical Disease Priority Review Voucher (PRV), Orphan Drug Act incentives, and Qualified Infectious Disease Product (QIDP) designation, subject to regulatory criteria.

Additional indications are supported by historical data and ongoing scientific collaborations, including select intracellular infectious diseases and biodefense-related pathogens; however, AliquantumRx is initially focused on achieving human proof-of-concept in liver-stage malaria.